Israel-founded biotech Quark has announced success in a Phase II trial of its treatment for preventing kidney damage during open-heart surgery. 300,000 such operations are performed annually in the US alone. Quark is now in Phase III trials to use the treatment in kidney transplants.
http://www.globes.co.il/en/article-quark-reports-positive-kidney-treatment-trial-1001199311